- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07635888
Silent Aspiration Following Extubation in the ICU (SAFE-ICU)
Incidence, Risk Factors, and Outcomes of Silent Aspiration Post Extubation in the ICU
Post-extubation dysphagia is common in critically ill patients and may lead to silent aspiration, which often remains undetected because patients do not exhibit overt clinical signs such as coughing or choking. Current bedside nursing swallow screening may fail to identify silent aspiration in patients recovering from prolonged mechanical ventilation.
The goal of this observational study is to learn about the incidence, risk factors, and clinical outcomes of silent aspiration in critically ill adult patients who require prolonged mechanical ventilation and are extubated in the ICU. The main questions it aims to answer are:
- How often does silent aspiration occur in ICU patients intubated for 5 days or longer after extubation?
- Can silent aspiration be present despite passing the routine bedside nursing swallow screen?
- What clinical factors are associated with silent aspiration?
- Is silent aspiration associated with worse clinical outcomes such as aspiration pneumonia, reintubation, prolonged ICU stay, ventilator-free days, or mortality? Participants who have been mechanically ventilated for 5 days or more will undergo routine bedside swallow screening followed by Fiberoptic Endoscopic Evaluation of Swallowing (FEES), considered the gold-standard diagnostic tool for detecting silent aspiration, within 72 hours after extubation. Researchers will compare bedside nursing swallow screening results with FEES findings to evaluate the diagnostic accuracy of bedside screening in detecting silent aspiration. Clinical data, swallowing assessment findings, and patient outcomes will also be collected and analyzed.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Background:
Post-extubation dysphagia (PED) is common in critically ill patients and is often multifactorial in origin, resulting from trauma, neuromuscular weakness, altered sensation, impaired cognition, and desynchronized breathing-swallowing coordination. Silent aspiration - defined as entry of oropharyngeal material below the vocal folds without overt clinical signs such as coughing or choking - has been reported in up to 69.3% of ICU patients undergoing instrumental assessment. Despite this, current clinical practice at many centers does not mandate instrumental swallow evaluation for patients who pass routine bedside nursing swallow screening.
Study Design:
This is a prospective observational study conducted in the ICU at Cleveland Clinic Abu Dhabi (CCAD). Informed consent will be obtained from all patients or their next of kin prior to enrollment.
Participants:
Adult ICU patients who have been mechanically ventilated for 5 or more days and are subsequently extubated will be eligible for enrollment. Exclusion criteria include: (1) tracheostomy; (2) do-not-reintubate orders; (3) pregnancy; and (4) absence of informed consent.
Procedures:
All enrolled patients will undergo the standard bedside nursing swallow screen per institutional protocol (CCAD PolicyTech). For the purpose of this study, Fiberoptic Endoscopic Evaluation of Swallowing (FEES) will be performed in all enrolled patients up to 72 hours of extubation, regardless of bedside screening results. FEES is a well-established, safe, and portable instrumental assessment that allows direct visualization of pharyngeal and laryngeal structures and detection of aspiration, including silent aspiration. FEES will only be performed after approval by the treating attending physician, and patients with contraindications (e.g., high bleeding risk, high oxygen requirements) will be excluded from the procedure.
Assessments:
FEES findings will be reported using standardized validated scales including the Penetration-Aspiration Scale (PAS), Dysphagia Severity Rating Scale (DSRS), Pharyngeal Residue Severity Rating Scale (PRSS), Murray Secretion Scale, and Airway Protection Scale. Clinical data collected will include age, sex, admitting diagnosis, reasons for intubation, duration of mechanical ventilation, oxygen requirements, bedside swallow screen findings, and clinical outcomes including aspiration pneumonia, reintubation, ventilator-free days, ICU and hospital length of stay, and mortality.
Statistical Analysis:
Descriptive statistics will be used to report the incidence of silent aspiration. Diagnostic accuracy (sensitivity, specificity, Cohen's kappa) of bedside nursing screening will be calculated using FEES as the reference standard. Multivariable logistic regression will identify independent predictors of silent aspiration and its association with clinical outcomes. A minimum sample of 274 patients will be recruited (based on an expected 20% incidence, 95% CI, 5% margin of error, 10% loss to follow-up).
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Contatto studio
- Nome: Jihad Mallat, MD, PhD
- Numero di telefono: +97125019000
- Email: mallatj@ccad.ae
Luoghi di studio
-
-
-
Abu Dhabi, Emirati Arabi Uniti
- Cleveland Clinic Abu Dhabi
-
Contatto:
- Jihad Mallat, MD PhD
- Numero di telefono: +97125019000
- Email: mallatj@ccad.ae
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Adult ICU patients requiring invasive mechanical ventilation for 5 days or longer
- Successful extubation after invasive mechanical ventilation
- Undergoing bedside nursing swallow screening after extubation
- Ability to undergo Fiberoptic Endoscopic Evaluation of Swallowing (FEES) within 72 hours after extubation
- Provision of informed consent by the patient or legally authorized representative
Exclusion Criteria:
- Presence of tracheostomy
- Do-not-reintubate orders/Allow natural death
- Pregnancy
- Absence of informed consent
- Contraindication to FEES as determined by the treating physician (e.g., high bleeding risk or severe oxygen requirements)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
ICU Patients Following Prolonged Mechanical Ventilation
Adult ICU patients intubated for 5 days or longer undergoing bedside swallow screening and Fiberoptic Endoscopic Evaluation of Swallowing (FEES) within 72 hours after extubation to assess silent aspiration
|
FEES will be performed within 72 hours after extubation to assess swallowing function and detect silent aspiration in ICU patients following prolonged mechanical ventilation.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Incidence of Silent Aspiration After Extubation
Lasso di tempo: Up to 72 hours after extubation
|
Silent aspiration identified by Fiberoptic Endoscopic Evaluation of Swallowing (FEES) in ICU patients intubated for 5 days or longer after extubation
|
Up to 72 hours after extubation
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Diagnostic Accuracy of Bedside Swallow Screening
Lasso di tempo: Up to 72 hours after extubation
|
Sensitivity and specificity of bedside nursing swallow screening for detecting silent aspiration using FEES as the reference standard
|
Up to 72 hours after extubation
|
|
Aspiration Pneumonia
Lasso di tempo: Up to 30 days after extubation
|
Incidence of aspiration pneumonia following extubation
|
Up to 30 days after extubation
|
|
Reintubation
Lasso di tempo: Up to 30 days after extubation
|
Need for reintubation after extubation
|
Up to 30 days after extubation
|
|
Ventilator-Free Days
Lasso di tempo: 28 days
|
Number of ventilator-free days after extubation
|
28 days
|
|
ICU Length of Stay
Lasso di tempo: Up to 24 weeks
|
Length of ICU stay after extubation
|
Up to 24 weeks
|
|
Hospital length of stay
Lasso di tempo: Up to 26 weeks
|
Total hospital length of stay
|
Up to 26 weeks
|
|
ICU Mortality
Lasso di tempo: Up to 24 weeks
|
Death occurring during ICU stay
|
Up to 24 weeks
|
|
Hospital Mortality
Lasso di tempo: Up to 26 weeks
|
Death occurring during hospitalization
|
Up to 26 weeks
|
|
Risk Factors Associated With Silent Aspiration
Lasso di tempo: Up to 26 weeks
|
Clinical factors independently associated with silent aspiration identified using multivariable analysis
|
Up to 26 weeks
|
|
Duration of Dysphagia
Lasso di tempo: Up to 3 months
|
Duration of post-extubation dysphagia identified by FEES
|
Up to 3 months
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Jihad Mallat, MD, PhD, Cleveland Clinic Abu Dhabi
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Processi patologici
- Attributi della malattia
- Infezioni delle vie respiratorie
- Infezioni
- Malattie delle vie respiratorie
- Malattie dell'apparato digerente
- Malattie gastrointestinali
- Malattie polmonari
- Malattie esofagee
- Polmonite
- Malattie otorinolaringoiatriche
- Malattie faringee
- Condizioni patologiche, segni e sintomi
- Malattia critica
- Disturbi della deglutizione
- Polmonite, Aspirazione
Altri numeri di identificazione dello studio
- A-2026-026
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .